Literature DB >> 15943957

Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey.

Gerry Oster1, Gale Harding, Ellen Dukes, John Edelsberg, Paul D Cleary.   

Abstract

UNLABELLED: Persons aged >65 years with pain caused by postherpetic neuralgia (PHN) were recruited via advertisements in 24 US newspapers and were mailed a questionnaire that addressed pain intensity (average, worst, least, current), pain interference (with general activity, mood, relations with other people, sleep, enjoyment of life), and health-related quality of life (using the EuroQoL health measure [EQ-5D] and a global rating scale). Respondents also were asked about their use of medication for shingles pain. A total of 385 persons completed the survey; 61% were >75 years of age. Mean (+/-standard deviation) duration of PHN was 3.3 (+/-4.0) years. Only about one half had taken prescription medication for shingles pain during the prior week; dosages were typically low. Mean average, worst, least, and current pain caused by shingles (0- to 10-point scale) was 4.6 (+/-2.1), 6.0 (+/-2.4), 2.9 (+/-2.3), and 4.0 (+/-2.7), respectively. Mean pain interference with general activity, mood, relations with other people, sleep, and enjoyment of life (0- to 10-point scale) was 3.7 (+/-3.1), 4.3 (+/-2.9), 3.0 (+/-2.8), 3.8 (+/-2.9), and 4.5 (+/-3.1), respectively. The mean EQ-5D health index score was 0.61; respondents rated their overall health as 65.7 (+/-21.1) on a 100-point scale. PHN causes substantial pain, dysfunction, and poor health-related quality of life in older persons, many of whom might be suboptimally treated. PERSPECTIVE: Many older persons (age >65 years) with PHN experience longstanding, severe, and debilitating pain and poor health-related quality of life; levels of dissatisfaction with treatment are high. Our study highlights the need for improved management of this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943957     DOI: 10.1016/j.jpain.2005.01.359

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  66 in total

1.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

2.  The association of symptoms with health outcomes in chronically ill adults.

Authors:  Lisa M Walke; Amy L Byers; William T Gallo; Jérôme Endrass; Terri R Fried
Journal:  J Pain Symptom Manage       Date:  2007-01       Impact factor: 3.612

3.  Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners.

Authors:  Ariel Berger; Piotr Kramarz; Gry Stine Kopperud; John Edelsberg; Gerry Oster
Journal:  Eur J Health Econ       Date:  2007-01-13

4.  US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?

Authors:  I-Chan Huang; Richard J Willke; Mark J Atkinson; William R Lenderking; Constantine Frangakis; Albert W Wu
Journal:  Qual Life Res       Date:  2007-04-06       Impact factor: 4.147

5.  Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Authors:  Thomas D Szucs; Reto W Kressig; Manto Papageorgiou; Werner Kempf; Jean-Pierre Michel; Anton Fendl; Xavier Bresse
Journal:  Hum Vaccin       Date:  2011-07-01

6.  Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.

Authors:  Hiltrud Liedgens; Nadine Hertel; Anja Gabriel; Mark Nuijten; Helen Dakin; Stephen Mitchell; Barbara Poulsen Nautrup
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Cost effectiveness of herpes zoster vaccine in Canada.

Authors:  Mehdi Najafzadeh; Carlo A Marra; Eleni Galanis; David M Patrick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Community and patient values for preventing herpes zoster.

Authors:  Tracy A Lieu; Ismael Ortega-Sanchez; G Thomas Ray; Donna Rusinak; W Katherine Yih; Peter W Choo; Irene Shui; Ken Kleinman; Rafael Harpaz; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

Authors:  Lee Moore; Vanessa Remy; Monique Martin; Maud Beillat; Alistair McGuire
Journal:  Cost Eff Resour Alloc       Date:  2010-04-30

Review 10.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.